Reference : Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial
Scientific journals : Article
Human health sciences : Multidisciplinary, general & others
http://hdl.handle.net/10993/26953
Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial
English
Knip, M. []
Åkerblom, H.K. []
Becker, D. []
Dosch, H.M. []
Dupre, J. []
Fraser, W. []
Howard, N. []
Ilonen, J. []
Krischer, J.P. []
Kordonouri, O. []
Lawson, M.L. []
Palmer, J.P. []
Savilahti, E. []
Vaarala, O. []
Virtanen, S.M. []
De Beaufort, Carine mailto [University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > >]
11-Jun-2014
JAMA : Journal of the American Medical Association
American Medical Association
311
22
2279-2287
Yes (verified by ORBilu)
0098-7484
1538-3598
Chicago
IL
[en] hydrolyzed infant formula ; Hydrolyzed infant formula and early β-cell autoimmunity
[en] Importance The disease process leading to clinical type 1 diabetes often starts during the first years of life. Early exposure to complex dietary proteins may increase the risk of β-cell autoimmunity in children at genetic risk for type 1 diabetes. Extensively hydrolyzed formulas do not contain intact proteins.

Objective To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of diabetes-associated autoantibodies in young children.

Design, Setting, and Participants A double-blind randomized clinical trial of 2159 infants with HLA-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1078 were randomized to be weaned to the extensively hydrolyzed casein formula and 1081 were randomized to be weaned to a conventional cows’ milk–based formula. The participants were observed to April 16, 2013.

Interventions The participants received either a casein hydrolysate or a conventional cows’ milk formula supplemented with 20% of the casein hydrolysate.

Main Outcomes and Measures Primary outcome was positivity for at least 2 diabetes-associated autoantibodies out of 4 analyzed. Autoantibodies to insulin, glutamic acid decarboxylase, and the insulinoma-associated–2 (IA-2) molecule were analyzed using radiobinding assays and islet cell antibodies with immunofluorescence during a median observation period of 7.0 years (mean, 6.3 years).

Results The absolute risk of positivity for 2 or more islet autoantibodies was 13.4% among those randomized to the casein hydrolysate formula (n = 139) vs 11.4% among those randomized to the conventional formula (n = 117). The unadjusted hazard ratio for positivity for 2 or more autoantibodies among those randomized to be weaned to the casein hydrolysate was 1.21 (95% CI, 0.94-1.54), compared with those randomized to the conventional formula, while the hazard ratio adjusted for HLA risk, duration of breastfeeding, vitamin D use, study formula duration and consumption, and region was 1.23 (95% CI, 0.96-1.58). There were no clinically significant differences in the rate of reported adverse events between the 2 groups.

Conclusions and Relevance Among infants at risk for type 1 diabetes, the use of a hydrolyzed formula, when compared with a conventional formula, did not reduce the incidence of diabetes-associated autoantibodies after 7 years. These findings do not support a benefit from hydrolyzed formula.
http://hdl.handle.net/10993/26953

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
knip et al. 2014 hydrolyzed infant formula.pdfAuthor postprint756.73 kBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.